Most health plans aren't using value frameworks to decide which prescription drugs they will cover, or how much to pay for them.
That's according to a new report from Washington, D.C.-based health care consulting comapny Avalere, which said that health plans are instead waiting for the frameworks to evolve and for physicians to buy in before they base decisions on them.
The framework initiative was launched in mid-2015 by the American Society of Clinical Oncology, Institute for Clinical and Economic Review, Memorial Sloan Kettering, and National Comprehensive Care Network as a means of helping stakeholders assess the value of drugs.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
